Drug Research

Vetter, a global CDMO, is making additional investments as part of its long-lead goals for continued expansion and to support customer needs. The company is investing €230 million in its new production building, which is currently under construction at its...

Lonza is planning to build a commercial-scale aseptic current good manufacturing practice (cGMP) filling line at its site in Stein, Switzerland. The new filling line will facilitate the aseptic filling of highly-potent antibody drug conjugates (ADCs) and lyophilisation under...

Gritgen Therapeutics Co., a biotechnology company focused on gene therapy products, reported the successful validation and launch of operations at its commercial GMP facility in Suzhou China for the production of Gritgen's phase III clinical and commercial product for...

Cellipont Bioservices has signed an agreement with Diakonos Oncology for the development of DOC1021, a cell therapy to treat glioblastoma multiforme (GBM). The parties will carry out the process development and current good manufacturing practice (cGMP) production of DOC1021 for...

Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) experts, Axol Bioscience. The collaboration aims to explore the incorporation of human iPSC-derived microglia into high-content...

BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and mucin domain-containing protein 3, also...

Agilent Technologies Inc. recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years. The scope of the...